The European Commission has approved ICOTYDE® for eligible psoriasis patients aged 12 and over. The once-daily oral peptide targets IL-23 directly and is backed by phase III data from about 2,500 participants.
Eligibility starts at age 12 and 40kg under the European Commission's decision. The approval covers adults and adolescents with moderate to severe plaque psoriasis who are candidates for systemic therapy. Icotrokinra is the first oral targeted peptide designed to block the IL-23 receptor directly.
Patients now have another systemic option without injections. Johnson & Johnson says the medicine is taken once a day. The clinical programme behind the decision combined skin-clearing results with a favourable safety profile.
Icotrokinra received a further regulatory milestone in 2026 when the U.S. Food and Drug Administration approved it for adults and adolescents aged 12 and over who weigh at least 40kg and have moderate to severe plaque psoriasis.
About 6.4 million people in Europe are estimated to have psoriasis. The chronic disease can affect physical wellbeing, emotional health and quality of life. The burden can be greater when plaques appear on visible or sensitive areas. Johnson & Johnson materials describing the European decision also cite the 6.4 million estimate.
The evidence came from the phase III ICONIC programme. About 2,500 patients took part across four studies. Icotrokinra met all primary efficacy endpoints. Adults and adolescents were included from the outset, rather than being studied in a separate later phase.
The trials covered difficult sites such as the genital area and scalp. Two studies compared icotrokinra with an active treatment. That gave the results a measure beyond placebo-controlled testing.
On 2 October 2026, Johnson & Johnson presented ICONIC-TOTAL phase III data at the EADV Congress showing that icotrokinra maintained efficacy for up to two years in high-impact psoriasis locations, including the scalp and genital area. The update shifts attention from initial skin clearance to durability in sites that can be especially difficult to treat.
In those comparative studies, about 70% of patients receiving icotrokinra achieved clear or almost clear skin on the IGA 0/1 scale. By week 16, a further 55% reached a PASI 90 response. That result indicates a high level of improvement in psoriasis severity.
These figures came from comparisons with an active treatment. They therefore add context beyond placebo-controlled testing.
Safety was central to the regulatory decision. Through week 16, the rate of adverse events stayed within 1.1% of the placebo rate. No new safety signals were identified through week 52. The findings came from the ICONIC clinical programme and supported the favourable regulatory assessment.
The drug has a narrow target. Icotrokinra binds to the IL-23 receptor with high affinity. In human T cells, it has shown potent and selective inhibition of IL-23 signalling. That pathway supports inflammation in moderate to severe psoriasis.
Systemic treatment remains important for many people with more extensive disease. An earlier clinical report also examined the wider move toward targeted care. Icotrokinra applies that approach to psoriasis through an oral peptide rather than an injectable therapy.
The once-daily format is being positioned as an alternative for eligible patients who may prefer oral treatment to injectable biologics. The choice will depend on clinical circumstances, patient preferences and regulatory practice.
The phase III ICONIC programme is still assessing icotrokinra's safety and efficacy in adults and adolescents aged 12 and over with moderate to severe plaque psoriasis. The European approval gives eligible patients a once-daily oral treatment that targets IL-23 directly. It is supported by comparative efficacy data and safety follow-up through one year.
Newer ICONIC-TOTAL findings presented by Johnson & Johnson at EADV indicate sustained efficacy in difficult-to-treat areas through two years. Icotrokinra is more than a change in formulation. It offers a distinct delivery and targeting option for patients who need systemic control.
